Do older women with breast cancer benefit from adjuvant chemotherapy?: Commentary

Nature Clinical Practice Oncology

Volumn 3, Issue 12, 2006, Pages 652-653

  Monfardini, Silvio ^a   Basso, Umberto ^a  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; TAMOXIFEN;

ADJUVANT THERAPY; AGE; AGED; BREAST CANCER; CANCER GRADING; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COHORT ANALYSIS; COMORBIDITY; DATA ANALYSIS; DISEASE FREE SURVIVAL; DRUG USE; EDUCATION; ETHNIC DIFFERENCE; FEMALE; FUNCTIONAL STATUS; HUMAN; INFORMATION PROCESSING; LOGISTIC REGRESSION ANALYSIS; LYMPH NODE METASTASIS; MASTECTOMY; MEDICAL DECISION MAKING; OUTCOME ASSESSMENT; POVERTY; PRIORITY JOURNAL; PROGNOSIS; RATING SCALE; RISK ASSESSMENT; SHORT SURVEY; TREATMENT OUTCOME; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT;

EID: 33751570171     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0671     Document Type: Short Survey

References (4)

1. Brunello A et al. (2005) Adjuvant chemotherapy for elderly patients (≥70 years) with early, high risk breast cancer: A retrospective analysis of 260 patients. Ann Oncol 16: 1276-1282
2. Basso U and Monfardini S (2004) Multidimensional geriatric evaluation in elderly cancer patients: A practical approach. Eur J Cancer Care 13: 424-433
3. Early Breast Cancer Trialists' Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview. Lancet 365: 1687-1717
4. Fargeot P et al. (2004) Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, nodepositive, elderly breast cancer patients: 6-year follow-up results of the French Adjuvant Study Group 08 Trial. J Clin Oncol 22: 4674-4682